期刊文献+

C-myc-siRNA通过调控ROS诱导子宫内膜癌细胞凋亡

C-myc-siRNA could Induce Apoptosis of Endometrial Carcinoma Cell Through Regulating Reactive Oxygen Species
原文传递
导出
摘要 为探讨原癌基因C-myc-siRNA对子宫内膜癌细胞凋亡的影响,本研究利用细胞计数盒(cell counting Kit-8, CCK-8)法分别检测C-myc-siRNA转染组和空载体转染组(Vector-NC)的子宫内膜癌细胞活力;蛋白免疫印迹法(Western blotting)分别检测C-myc-siRNA转染组和空载体转染组(Vector-NC)的子宫内膜癌细胞凋亡蛋白Bax以及抗凋亡蛋白Bcl-2的变化;流式细胞仪分别检测C-myc-siRNA转染组和空载体转染组(Vector-NC)活性氧簇(reactive oxygen species, ROS)的变化;蛋白免疫印迹法(Western blotting)分别检测预处理NAC (ROS抑制剂)后,C-myc-siRNA转染组和空载体转染组(Vector-NC)的子宫内膜癌细胞凋亡相关蛋白Bax以及Bcl-2的变化。结果表明:C-myc-siRNA转染子宫内膜癌细胞后,促凋亡相关蛋白Bax的表达显著高于空载体转染组,且抗凋亡相关蛋白Bcl-2的表达明显低于空载体转染组(p<0.05);C-myc-siRNA转染子宫内膜癌细胞后,细胞ROS水平明显增加(p<0.05);NAC预处理显著减弱C-myc-siRNA对子宫内膜癌细胞凋亡的促进作用(p<0.05)。本研究结论表明,C-myc-siRNA能够通过调控ROS诱导子宫内膜癌细胞凋亡。 In order to discuss the effects of C-myc-siRNA on the apoptosis of endometrial carcinoma cell.In this research,Cell Counting Kit-8 was used to detect endometrial carcinoma cell viability of C-myc-siRNA-transfected group and Vector-NC group.Western blotting was used to detect the changes of endometrial carcinoma apoptosis protein Bax and anti-apoptosis protein Bcl-2 in C-myc-siRNA transfected group and Vector-NC group.Flow cytometry(FCM)was used to evaluate the changes of reactive oxygen species(ROS)in C-myc-siRNA transfected group and Vector-NC group.Western blot was used to detect the changes of endometrial carcinoma apoptosis related protein Bax and Bcl-2 in C-myc-siRNA transfected group and Vector-NC group after the pre-treatment with NAC(ROS inhibitor).The results revealed that after C-myc-siRNA transfected endometrial carcinoma cell,the expression of pro-apoptotic related protein Bax was significantly higher than that in Vector-NC group and the expression of anti-apoptotic related protein Bcl-2 was significantly lower than that in Vector-NC group(p<0.05).After C-myc-siRNA transfected endometrial carcinoma cell,the ROS level of endometrial carcinoma cell was significantly higher(p<0.05).Pretreatment with NAC significantly weakened the acceleration of C-myc-siRNA on the apoptosis of endometrial carcinoma cell(p<0.05).The conclusion of this study demonstrated that C-myc-siRNA could induce the apoptosis of endometrial carcinoma cell by the regulation of reactive oxygen species.
作者 王爱勤 赵洁 郝汇平 丁孝娥 Wang Aiqin;Zhao Jie;Hao Huiping;Ding Xiao’e(The People’s Hospital of Guangrao,Dongying,257300;Jinan Second Maternal and Child Health Hospital,Jinan,271100;Shouguang Maternity and Child Care Hospital,Weifang,262700)
出处 《基因组学与应用生物学》 CAS CSCD 北大核心 2019年第3期1454-1457,共4页 Genomics and Applied Biology
基金 国家卫生计生委医药卫生科技发展中心计划项目(201607号)资助
关键词 C-myc-siRNA 子宫内膜癌细胞 ROS 凋亡 C-myc-siRNA Endometrial carcinoma cell ROS Apoptosis
  • 相关文献

参考文献1

二级参考文献22

  • 1Mark F van Delft,David CS Huang.How the Bcl-2 family of proteins interact to regulate apoptosis[J].Cell Research,2006,16(2):203-213. 被引量:39
  • 2殷杰,钟苗,冯兰芳,朱炳阳,唐圣松,雷小勇.Bcl-2 siRNA增强HepG2细胞对5-氟尿嘧啶敏感性[J].南华大学学报(医学版),2007,35(4):503-506. 被引量:1
  • 3Tsujmoto Y, Gorham J , Croce CM, et al. The t (14,18)chromo- some translocations involved in B - cell neuoplasms result from mis- takes in VDJ joining [ J ]. Science , 1985,229 (4720) : 1390 - 1393.
  • 4Tortora G, Caputo R, Damiano V, et al. Combined targeted inhi- bition of bcl - 2, bcl - xl, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity [ J ]. Clin Cancer Res, 2003,9 ( 2 ) : 866 - 871.
  • 5Smith SR, Jin F, Joshi I. Enhanced efficacy of therapy with anti- sense BCL - 2 oligonucleotides plus anti - CD20 monoclonal antibody in scid mouse/human lymphoma xenografts [ J ]. Mol Cancer Ther,2004,3 ( 12 ) : 1693 - 1699.
  • 6Waters JS, Webb A, Cunningham D,et al. Phase I clinical and pharmacokinetic study of Bcl - 2 antisense oligonucleotide therapy in patients with non - Hodgkin's lymphoma [ J ]. J Clin Oncol, 2000,18(9) :1812 - 1823.
  • 7Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodyna- mic studies of G3139, a Bcl- 2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leu- kemia [ J ]. Blood ,2003,101 ( 2 ) :425 - 432.
  • 8Waters JS, Webb A, Curmingham D, et al. Phase I clinical and pharmacokinetic study of bcl - 2 antisense oligonucleotide therapy in patients with non - Hodgkin's lymphoma [ J ]. J Clin Oncol, 2000,18(9) :1812 - 1823.
  • 9Chi KN, Gleave ME, Klasa R, et al. A phase I dose -finding study of combined treatment with an antisense Bcl - 2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone -refractory prostate cancer[ J]. Clin Cancer Res,2001, 7 (12) :3920 - 3927.
  • 10Tolcher AW. Preliminary phase I results of G3139 ( bcl - 2 anti- sense oligonucleotide) therapy in combination with docetaxel in hormone - refractory prostate cancer [ J]. Semin Oneol, 2001,28 (4 Suppl 15) :67 -70.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部